NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free AVTE Stock Alerts $19.83 -1.73 (-8.02%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$19.59▼$21.6850-Day Range$19.83▼$30.7552-Week Range$9.41▼$32.42Volume79,129 shsAverage Volume137,679 shsMarket Capitalization$553.26 millionP/E RatioN/ADividend YieldN/APrice Target$49.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aerovate Therapeutics alerts: Email Address Aerovate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside148.8% Upside$49.33 Price TargetShort InterestBearish10.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 6 Articles This WeekInsider TradingSelling Shares$2.38 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.78) to ($2.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector839th out of 925 stocksPharmaceutical Preparations Industry396th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingAerovate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAerovate Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aerovate Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.43% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 50.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTE. Previous Next 2.7 News and Social Media Coverage News SentimentAerovate Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aerovate Therapeutics this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,379,544.00 in company stock.Percentage Held by Insiders19.30% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Aerovate Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aerovate Therapeutics are expected to decrease in the coming year, from ($2.78) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aerovate Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Aerovate Therapeutics Stock (NASDAQ:AVTE)Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More AVTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTE Stock News HeadlinesMay 4, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Marinus Verwijs Sells 1,981 SharesApril 21, 2024 | insidertrades.comBenjamin T. Dake Sells 6,853 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockMay 11, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 19, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Sells $247,000.00 in StockApril 13, 2024 | insidertrades.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 7,500 Shares of StockApril 12, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Director Sells $334,478.30 in StockMay 5, 2024 | americanbankingnews.comMarinus Verwijs Sells 1,981 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockMay 5, 2024 | americanbankingnews.comTimothy P. Noyes Sells 11,357 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) StockMay 11, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 20, 2024 | investing.comAerovate Therapeutics exec sells shares worth over $153,000April 20, 2024 | investing.comAerovate Therapeutics CEO sells over $246k in company stockApril 4, 2024 | finance.yahoo.comAerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 SharesApril 2, 2024 | markets.businessinsider.comAerovate Therapeutics: Poised for Market Capitalization Growth on IMPAHCT Trial SuccessApril 1, 2024 | msn.comAerovate Therapeutics (NASDAQ:AVTE) on the Verge of Substantial GrowthMarch 27, 2024 | globenewswire.comAerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceMarch 27, 2024 | finance.yahoo.comAerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023March 26, 2024 | finanznachrichten.deAerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 26, 2024 | markets.businessinsider.comAerovate Therapeutics: A Strong Buy Ahead of Key Clinical Data ReleaseMarch 25, 2024 | benzinga.comRecap: Aerovate Therapeutics Q4 EarningsMarch 25, 2024 | investorplace.comAVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023March 25, 2024 | markets.businessinsider.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 25, 2024 | globenewswire.comAerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsMarch 24, 2024 | morningstar.comAerovate Therapeutics Inc AVTEMarch 21, 2024 | finance.yahoo.comInsider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...March 21, 2024 | finance.yahoo.comChief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE)March 6, 2024 | globenewswire.comAerovate Therapeutics Board of Directors Appoints Habib Dable as Board ChairFebruary 26, 2024 | benzinga.comAerovate Therapeutics Stock (NASDAQ:AVTE) Dividends: History, Yield and DatesSee More Headlines Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/11/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$49.33 High Stock Price Target$65.00 Low Stock Price Target$35.00 Potential Upside/Downside+148.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.62% Return on Assets-55.08% Debt Debt-to-Equity RatioN/A Current Ratio7.04 Quick Ratio7.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book5.01Miscellaneous Outstanding Shares27,900,000Free Float22,515,000Market Cap$553.26 million OptionableOptionable Beta1.40 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 62)CEO & Director Comp: $936.9kMr. George A. Eldridge (Age 61)CFO & Treasurer Comp: $658.6kMr. Timothy J. Pigot (Age 53)Chief Commercial Officer Comp: $584.6kDr. Benjamin T. Dake Ph.D. (Age 48)Founder, President, COO & Secretary Comp: $435.5kDr. Marinus Verwijs Ph.D. (Age 48)Chief Technical Officer Comp: $439.88kDr. Ralph W. Niven M.B.A. (Age 64)M.R, Ph.D., Pharm.S, Chief Scientific Officer Comp: $372.33kMr. Hunter Gillies M.D. (Age 58)Chief Medical Officer Comp: $512.74kMs. Donna DeaHead of Regulatory AffairsMs. Susan FischerExecutive Vice President of Development OperationsMr. Stephen K. YuSenior Vice President of QualityMore ExecutivesKey CompetitorsArriVent BioPharmaNASDAQ:AVBPIGM BiosciencesNASDAQ:IGMSAvid BioservicesNASDAQ:CDMOApplied TherapeuticsNASDAQ:APLTAstria TherapeuticsNASDAQ:ATXSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 45,444 shares on 5/10/2024Ownership: 2.410%Marinus VerwijsSold 1,981 sharesTotal: $41,640.62 ($21.02/share)Timothy P. NoyesSold 11,357 sharesTotal: $231,001.38 ($20.34/share)Benjamin T DakeSold 6,853 sharesTotal: $153,301.61 ($22.37/share)Timothy P. NoyesSold 10,000 sharesTotal: $247,000.00 ($24.70/share)View All Insider TransactionsView All Institutional Transactions AVTE Stock Analysis - Frequently Asked Questions Should I buy or sell Aerovate Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVTE shares. View AVTE analyst ratings or view top-rated stocks. What is Aerovate Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 1-year price objectives for Aerovate Therapeutics' shares. Their AVTE share price targets range from $35.00 to $65.00. On average, they expect the company's share price to reach $49.33 in the next year. This suggests a possible upside of 148.8% from the stock's current price. View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts. How have AVTE shares performed in 2024? Aerovate Therapeutics' stock was trading at $22.63 at the start of the year. Since then, AVTE stock has decreased by 12.4% and is now trading at $19.83. View the best growth stocks for 2024 here. When is Aerovate Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our AVTE earnings forecast. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) released its quarterly earnings data on Monday, March, 25th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.06. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share. Who are Aerovate Therapeutics' major shareholders? Aerovate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.41%). Insiders that own company stock include Benjamin T Dake, Cormorant Asset Management, Lp, David S Grayzel, George A Eldridge, Hunter Gillies, Marinus Verwijs, Ralph Niven and Timothy P Noyes. View institutional ownership trends. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVTE) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
